Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

OBJECTIVES: This exploratory analysis investigated the potential use of the multibiomarker disease activity (MBDA) score to support biosimilarity assessments using data from two randomised controlled trials (RCTs) of biosimilar infliximab (IFX-qbtx) and biosimilar adalimumab (ADL-afzb) versus EU-sou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kay, Jonathan, Bock, Amy E, Rehman, Muhammad, Zhang, Wuyan, Zhang, Min, Iikuni, Noriko, Alvarez, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528718/
https://www.ncbi.nlm.nih.gov/pubmed/36180101
http://dx.doi.org/10.1136/rmdopen-2022-002423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528718/
https://www.ncbi.nlm.nih.gov/pubmed/36180101
http://dx.doi.org/10.1136/rmdopen-2022-002423

Ejemplares similares